Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290983 | 1.00 | PDK2 (0.46) | PDK2MAPK1L3MBTL1CYSLTR2CYSLTR1 | |
| SCHEMBL3292496 | 0.88 | MAOB (0.42) | KCNH2CYP2D6 | |
| SCHEMBL3292503 | 0.88 | MAOB (0.42) | KCNH2CYP2D6 | |
| SCHEMBL13558492 | 0.83 | KCNH2 (0.36) | KCNH2CYP2D6 | |
| SCHEMBL13558499 | 0.83 | ACHE (0.41) | KCNH2CYP2D6 | |
| SCHEMBL3291327 | 0.81 | MAPK1 (0.47) | PDK2MAPK1L3MBTL1CYSLTR2CYSLTR1 | |
| SCHEMBL3291333 | 0.81 | MAPK1 (0.47) | PDK2MAPK1L3MBTL1CYSLTR2CYSLTR1 | |
| SCHEMBL3295098 | 0.79 | TAAR1 (0.51) | — | |
| SCHEMBL5245788 | 0.78 | LMNA (0.46) | L3MBTL1TSHRMMP13CYP2D6 | |
| SCHEMBL5408880 | 0.78 | LMNA (0.46) | L3MBTL1TSHRMMP13CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828106-B1 | METHAMPHETAMINE DERIVATIVES AND CONJUGATES FOR IMMUNOASSAY | ROCHE DIAGNOSTICS GMBH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-7732160-B2 | Methamphetamine derivatives and conjugates for immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080050843-A1 | METHAMPHETAMINE DERIVATIVES AND CONJUGATES FOR IMMUNOASSAY | HUI RAYMOND A | 2008-02-28 | — | — | US | disclosed |
| US-7294649-B2 | Methamphetamine derivatives and conjugates for immunoassay | ROCHE DIAGNOSTICS OPERATINS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20060134711-A1 | Methamphetamine derivatives and conjugates for immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134711-A1 | Methamphetamine derivatives and conjugates for immunoassay | PNMT, COMT, MCHR1 | PDK2 3713/4885MAPK1 660/4885L3MBTL1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.